

## Management Team

### Ted Schroeder

President, Chief Executive Officer,  
Director

### Kevin Finney

Chief Operating Officer

### Evelyn Ellis-Grosse, PhD

Chief Scientific Officer

### Cam Gallagher

Chief Business Officer

### Richard Vincent

Chief Financial Officer

### Robert DiVasto, PE

Senior Vice President,  
Manufacturing and Supply

### Kristina Haeckl

Vice President of Regulatory Affairs  
and Quality Systems

### David Skarinsky

Vice President of Clinical Operations

### Paul Eckburg, MD

Acting Chief Medical Officer

### Kim Sweeney, PharmD

Senior Director, Medical Affairs

## Board of Directors

### Cam Garner

Chairman

### Ted Schroeder

President, Chief Executive Officer,  
and Director

### Patrick Heron

Director, Frazier Healthcare Partners

### David Hirsch, MD, PhD

Director, Longitude Capital

### Stephen Newman, MD

Independent Board Member

### Andrew N. Schiff, MD

Observer, Aisling Capital

## About Zavante Therapeutics

Zavante is passionately committed to improving the care and outcomes of hospitalized patients by identifying, developing and commercializing novel therapeutics that address significant unmet medical needs.

Zavante's lead product candidate is an investigational, first-in-class injectable antibiotic under development to combat serious, life-threatening infections, including those due to multi-drug resistant (MDR) bacteria. In 2017, Zavante completed its pivotal Phase 2/3 ZEUS™ study, in which ZOLYD™ (fosfomycin for injection) demonstrated efficacy and safety for the treatment of patients with complicated urinary tract infections (cUTI), the product's first indication. The company expects to file a New Drug Application utilizing the FDA's 505(b)(2) pathway in early 2018.

The company is backed by leading life science investors Frazier Healthcare Partners, Longitude Capital and Aisling Capital. Each firm has an excellent track record of identifying clinically de-risked assets and building successful anti-infective companies.

## Zavante® Timeline & Financing History

- September 2014 ▼ ZOLYD granted QIDP designation for cUTI
- June 2015 ▼ Zavante Therapeutics secured first private investment
- December 2015 ▼ FDA agreed to single pivotal trial for ZOLYD
- December 2015 ▼ Three additional indications granted QIDP designation
- December 2015 ▼ Fast-track granted for all four indications
- December 2015 ▼ Zavante raised \$10+ million convertible notes
- March 2016 ▼ Zavante raised \$35 million new Series A financing
- July 2016 ▼ First patient enrolled in ZOLYD ZEUS™ study
- August 2016 ▼ Infectious disease experts joined Scientific Advisory Board
- April 2017 ▼ ZOLYD met primary endpoint in pivotal ZEUS study
- November 1st ▼ Pre-NDA Meeting

## Therapeutic Focus

*Growing antimicrobial resistance creates a significant demand for novel therapies.*

Bacterial resistance to currently available antimicrobials has reached alarmingly high levels in recent decades, resulting in a global health crisis. Antibiotic treatment options with differing mechanisms of action are urgently needed, particularly agents with activity against MDR Gram-negative bacteria.

Zavante believes it is uniquely poised to address the critical need for new antibiotics through the development of ZOLYD, an antibiotic with a broad spectrum of Gram-negative and Gram-positive activity, including activity against MDR pathogens associated with life-threatening infections, such as carbapenem resistant enterobacteriaceae.

*“The lack of available and effective antibiotics for these life-threatening multidrug-resistant pathogens has created an important unmet medical need. An antibiotic with a unique mechanism of action like ZOLYD would be an important addition to our antibacterial armamentarium when treating seriously ill patients in the hospital.”*

**George Drusano, MD,**  
Professor of Medicine and Director of the Institute for Therapeutic Innovation, Department of Medicine, College of Medicine, University of Florida

## Upcoming Milestones

- ▼ New Drug Application for ZOLYD<sup>™</sup> expected to be filed with FDA in early 2018.

## Media Relations Contact

**Ian Stone**  
Canale Communications  
ian@canalecomm.com  
619-849-5388

## ZOLYD<sup>™</sup>: Addressing Hospital Infections


ZOLYD (fosfomycin for injection) is an investigational, first-in-class epoxide antibiotic with a broad spectrum of bactericidal *in vitro* activity against both Gram-negative and Gram-positive bacteria, including activity against most contemporary multi-drug resistant (MDR) strains that threaten hospitalized patients. ZOLYD utilizes a new dosing approach to optimize the compound’s pharmacokinetics and pharmacodynamics. Zavante believes that these attributes, along with extensive clinical experience outside of the U.S., support ZOLYD as a first-line treatment for complicated urinary tract infections (cUTI) suspected to be caused by MDR pathogens. Non-clinical data have also shown that ZOLYD acts synergistically with certain other antibiotics to improve bacterial killing and restore susceptibility to infective agents otherwise demonstrating resistance.

The pivotal ZEUS<sup>™</sup> (ZTI-01 Efficacy and Safety) study was designed to obtain regulatory approval for ZOLYD for the treatment of cUTI, including acute pyelonephritis (AP). ZOLYD met the primary endpoint of statistical non-inferiority to piperacillin/tazobactam in the ZEUS trial in this patient population. Approximately 25% of cUTIs are caused by multi-drug resistant bacteria with limited treatment options available. Fosfomycin IV has an established safety profile based upon its use in markets outside the U.S., where it has been utilized for over 40 years in nine indications.

The FDA has granted ZOLYD Qualified Infectious Disease Product (QIDP) and Fast Track designations for:

- ▼ Complicated urinary tract infections (cUTI)
- ▼ Complicated intra-abdominal infections (cIAI)
- ▼ Hospital-acquired bacterial pneumonia (HABP)/ Ventilator-associated bacterial pneumonia (VABP)
- ▼ Acute bacterial skin and skin structure infections (ABSSSI)

These designations make ZOLYD eligible for certain incentives including priority FDA review and an additional five years of market exclusivity under the Generating Antibiotic Incentives Now (GAIN) Act.



ZOLYD is an investigational medication that has not been found by the U.S. Food and Drug Administration to be safe or effective for any indication. This fact sheet contains forward-looking statements within the meaning of U.S. federal securities laws, including statements about the anticipated effectiveness of ZOLYD in treating serious infections in hospitalized patients, and the company’s plans and timing for submitting a new drug application for ZOLYD. The company’s actual results may differ materially from those indicated in the forward-looking statements. May 2017 © Copyright 2017 Zavante Therapeutics, Inc. All rights reserved. ZAVANTE, ZOLYD and ZEUS are trademarks or registered trademarks of Zavante Therapeutics, Inc.